BCDAHealthcare · BiotechnologyThe 2 Wall Street analysts covering BioCardia, Inc. hold a median 12-month price target of $16 — +1764.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores BioCardia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own BioCardia, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on BCDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1764.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 22 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Sept 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 July 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2022 | Dawson James | Downgrade | Neutral | — |
| 20 Dec 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Apr 2021 | Dawson James | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 97% of US stocks
Cheaper than 68% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCDA appears on the weeks it earns a place.
BioCardia, Inc. (BCDA) was added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026, according to Zacks Investment Research.
Why it matters — BCDA shareholders would care because a Zacks Strong Sell ranking signals the research firm's negative near-term outlook for the stock.
The 2 Wall Street analysts covering BioCardia, Inc. have a median 12-month price target of $16, with estimates ranging from $6 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering BioCardia, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCardia, Inc. 36 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, BioCardia, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1764.8% from the last close, and Ticker Nerd's factor model ranks BioCardia, Inc. 36 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioCardia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $25 over the next 12 months.
BioCardia, Inc. returned -61.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
BioCardia, Inc. is a clinical-stage regenerative medicine company specializing in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
The most recent item we track (Zacks Investment Research, 28 July 2026): "New Strong Sell Stocks for July 28th". BioCardia, Inc. (BCDA) was added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026, according to Zacks Investment Research.
BioCardia, Inc. is a clinical-stage regenerative medicine company specializing in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program, CardiAMP, is an autologous mononuclear cell therapy derived from bone marrow that is being developed for ischemic heart failure and chronic myocardial ischemia with refractory angina. CardiAMP is manufactured at the patient's bedside using BioCardia's proprietary cell processing system and delivered via a minimally invasive catheter-based approach. The company also develops CardiALLO and PulmALLO, allogeneic mesenchymal stem cell therapies designed to treat heart failure and acute respiratory distress syndrome. BioCardia provides the Helix biotherapeutic delivery system, a minimally invasive platform enabling targeted delivery of biologic agents to the heart, along with navigation tools like the Morph deflectable guides and Heart3D fusion imaging technology. Headquartered in Sunnyvale, California, BioCardia addresses critical unmet medical needs in cardiovascular and pulmonary disease treatment through its advancing clinical trial programs and innovative delivery technologies.
CEO Dr. Peter A. Altman Ph.D. · 17 employees · United States · https://www.biocardia.com